Systemic testosterone for the treatment of female sexual interest and arousal disorder (FSIAD) in the postmenopause.

Laura Ribera Torres Sònia Anglès-AcedoLaura López ChardiEduard Mension Coll Camil Castelo-Branco

Published in: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (2024)

Despite having testosterone as a valuable tool, therapeutic strategies are lacking in the pharmacological field of HSDD/FSIAD. Neuroimaging studies could provide valuable information regarding the sexual desire substrate and suggest the potential application of already approved drugs for women with a good safety profile. The use of validated instruments for HSDD in postmenopausal women, considering the level of distress, is necessary to be able to draw robust conclusions on the evaluated treatments.

Keyphrases

postmenopausal women
bone mineral density
replacement therapy
mental health
healthcare
health information
human health
risk assessment
patient reported outcomes
smoking cessation
drug induced
case control
body composition
social media
drug administration